Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2021

View Archived Issues

Sinopharm CNBG's COVID-19 vaccine approved in China

Promising phase II data presented for BT-11 in ulcerative colitis

Nanjing Ruijie Pharma discloses new NR1H4 agonists

PT-101 shows safety and ability to selectively expand Tregs in healthy volunteers

Vivoryon Therapeutics patents meprin A inhibitors

Ayala plans pivotal phase II/III RINGSIDE study of AL-102 in desmoid tumors

Ryvu Therapeutics identifies hSTING receptor agonists

Enterprise Therapeutics divulges ANO1 activators

FDA clears IND for phase I/II study of FBX-101 in patients with Krabbe disease

Karuna opens enrollment in phase III study of KarXT in acutely psychotic schizophrenia

Protein introns, "inteins", are antifungal targets

Pfizer initiates first-in-human study of PF-07209960 for advanced or metastatic solid tumors

Novartis presents new NPR1-targeting antibodies

Novel anti-NPM1c CAR-T cells demonstrate efficacy in models of AML

ID-93/GLA-SE tuberculosis vaccine demonstrates safety and immunogenicity in phase IIa trial

BET inhibitor ODM-207 is safe in fist-in-human study in patients with solid tumors

Luye initiates phase I trial of monthly microsphere injection LY-03009

New phase II trial evaluates SCD-044 for moderate to severe plaque psoriasis

Topline phase II data reported for ATYR-1923 in hospitalized COVID-19 patients

Ryvu submits CTA to begin phase I/II trial of RVU-120 in solid tumors

EMA validates Opdivo filing in first-line gastric cancer, GEJ and esophageal adenocarcinoma

CANTATA study of telaglenastat in renal cell carcinoma misses primary endpoint

New phase III trial evaluates tisotumab vedotin for recurrent or metastatic cervical cancer